Table 2.
Mean scale scores for preuse and postuse.
| Scale | Preuse score, mean (SD) | Postuse score, mean (SD) | Difference (95% CI) | P valuea | |||||
| PEb | |||||||||
|
|
PE1: This platform will be useful during outreach screening. | 4.04 (0.81) | 4.63 (0.49) | +0.58 (0.21 to 0.96) | .006 | ||||
|
|
PE2: The platform will enable me to make more accurate diagnoses. | 3.42 (0.72) | 3.88 (0.95) | +0.46 (0.15 to 0.76) | .008 | ||||
|
|
PE3c: I do not expect that this platform can be used for a reliable eye exam. | 3.29 (0.95) | 3.33 (0.96) | +0.04 (−0.54 to 0.62) | .89 | ||||
|
|
PE4: More glaucoma cases can be detected by the platform. | 3.38 (0.71) | 4.17 (0.96) | +0.79 (0.34 to 1.24) | .005 | ||||
|
|
PE5d: The results presented are informative enough to make referral decisions. | —e | 4.21 (0.72) | — | — | ||||
| EEf | |||||||||
|
|
EE1: I think the platform will make it easy for me to administer visual field tests. | 3.88 (0.61) | 4.79 (0.41) | +0.92 (0.59 to 1.24) | <.001 | ||||
|
|
EE2: I think learning how to use the platform will be easy. | 4.00 (0.72) | 4.71 (0.46) | +0.71 (0.44 to 0.97) | <.001 | ||||
|
|
EE3: It will be easy to have patients wear the virtual reality headset. | 3.63 (0.92) | 4.42 (0.88) | +0.79 (0.42 to 1.16) | .001 | ||||
|
|
EE4: Compared with the FDTg, administering visual field testing with this platform will be easier. | 3.33 (0.82) | 4.29 (0.85) | +0.96 (0.46 to 1.46) | .002 | ||||
|
|
EE5: The platform will be easier for patients from rural areas compared with the FDT. | — | 4.25 (1.19) | +0.58 (−0.01 to 1.18) | .047 | ||||
|
|
EE6: Patients can easily use a joystick for responses. | 3.71 (0.95) | 4.25 (0.74) | +0.54 (0.15 to 0.94) | .01 | ||||
|
|
EE7d: My interaction with the platform was clear and understandable. | — | 4.42 (0.58) | — | — | ||||
| SIh | |||||||||
|
|
SI1: I think the senior ophthalmologist staff will recommend the platform for glaucoma screening. | 3.67 (0.87) | 4.08 (0.93) | +0.42 (−0.10 to 0.93) | .08 | ||||
|
|
SI2: In general, I think the platform will be seen as useful by the ophthalmology department. | 3.83 (0.76) | 4.63 (0.49) | +0.79 (0.46 to 1.12) | .001 | ||||
|
|
SI3: My colleagues will support my use of this platform. | 3.67 (0.96) | 4.46 (0.66) | +0.79 (0.38 to 1.20) | .002 | ||||
|
|
SI4: My patients will be open to the use of this platform. | 3.46 (0.98) | 4.50 (0.59) | +1.04 (0.58 to 1.50) | .001 | ||||
|
|
SI5: If I use the platform, I will be considered as an advocate of technology by my colleagues. | 4.04 (0.86) | 4.17 (0.92) | +0.13 (−0.23 to 0.48) | .47 | ||||
| FCi | |||||||||
|
|
FC1: All the necessary resources to use the platform will be easily available. | 3.33 (1.13) | 4.00 (1.02) | +0.67 (0.22 to 1.11) | .007 | ||||
|
|
FC2: The platform will not be expensive for our clinic to purchase. | 3.75 (1.03) | 4.21 (0.83) | +0.46 (0.01 to 0.91) | .046 | ||||
|
|
FC3: The platform can be used with our existing infrastructure. | 3.88 (0.95) | 4.13 (0.85) | +0.25 (−0.24 to 0.74) | .21 | ||||
|
|
FC4: Charging the smartphone will not be a challenge, even during outreach missions. | 3.75 (0.99) | 4.29 (0.75) | +0.54 (0.11 to 0.97) | .02 | ||||
|
|
FC5c,d: The platform cannot be used in the current setting. | — | 3.63 (1.21) | — | — | ||||
| BIj | |||||||||
|
|
BI1: If made readily available, I intend to use the platform in the near future. | 4.08 (0.50) | 4.67 (0.48) | +0.58 (0.34 to 0.83) | <.001 | ||||
|
|
BI2: When available, I would like to take the platform along with other kits for outreach missions. | 3.96 (0.62) | 4.50 (0.59) | +0.54 (0.21 to 0.87) | .005 | ||||
|
|
BI3: I am looking forward to using this platform when it is available. | 4.00 (0.42) | 4.67 (0.48) | +0.67 (0.46 to 0.87) | <.001 | ||||
aWilcoxon signed-rank test (nonparametric).
bPE: performance expectancy.
cInverted items.
dExtra item included only in the postuse questionnaire.
eItem included in preuse only or postuse only and data not available.
fEE: effort expectancy.
gFDT: frequency doubling technology.
hSI: social influence.
iFC: facilitating condition.
jBI: behavioral intention.